{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"827"}],"units":"Participants"}],"description":"Phase 1: RP2D","groups":[{"description":"All Phase 1 Participants who received Selpercatinib (20 mg - 240 mg) orally once daily (QD) or twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.","id":"OG000","title":"Phase 1 - Selpercatinib (All Participants)"}],"paramType":"NUMBER","populationDescription":"All Participants who received at least 1 or more doses of selpercatinib and had evaluable data for this outcome.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (cycle length = 28 days)","title":"Phase 1: Recommended Phase 2 Dose (RP2D)","type":"PRIMARY","unitOfMeasure":"milligrams"}